Taste and smell changes in testicular cancer patients treated with cisplatin based chemotherapy

Published: 12-04-2012 Last updated: 30-04-2024

Primary Objective: To investigate the nature, prevalence, and duration of taste and smell changes in patients with disseminated testicular cancer treated with cisplatin based chemotherapy (BEP or EP).Secondary Objective(s): -To explore the short-...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON37350

Source ToetsingOnline

Brief title Taste, smell, and chemotherapy (TASTY)

Condition

- Other condition
- Reproductive neoplasms male malignant and unspecified

Synonym taste and smell

Health condition

smaak- en geurfunctie

Research involving

Human

1 - Taste and smell changes in testicular cancer patients treated with cisplatin bas ... 25-05-2025

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Groningen **Source(s) of monetary or material Support:** Campina,Nutricia,Top Institute Food and Nutrition

Intervention

Keyword: Cancer, Nutrition, Smell, Taste

Outcome measures

Primary outcome

Scores of gustatory and olfactory function of patients with disseminated testicular cancer treated with cisplatin based chemotherapy will be investigated using physiological tests (taste strips and *Sniffin* Sticks*) and using a questionnaire on taste and smell function to investigate the subjective perception of taste and smell function among these patients. During the chemotherapeutic treatment the measurements will be re-assessed several times to investigate possible changes in gustatory and olfactory function before, during and after chemotherapy. Measurements will also be carried out 1, 3, 5 and 7 years after chemotherapy to investigate possible changes in gustatory and olfactory function in the long-term.

Secondary outcome

The secondary parameters are food preference, dietary intake, quality of life, BMI, body composition (bone and fat mass), audiograms, BRS, blood glucose level and DNA. We will focus on changes in these parameters due to changes in gustatory and olfactory function as a consequence of chemotherapy.

Study description

Background summary

Taste and smell abnormalities are common in cancer patients undergoing chemotherapy, with a prevalence ranging from 46% to 77% for taste changes, and 35% to 75% for smell changes. These chemosensory changes are distressing for patients and can lead to changes in appetite, food choice, and nutrient intake. These changes can result in malnutrition and weight loss. Possibly, also unhealthy eating patterns can be developed due to these taste and smell changes, given the high prevalence of obesity among survivors of certain cancer types.

Study objective

Primary Objective:

To investigate the nature, prevalence, and duration of taste and smell changes in patients with disseminated testicular cancer treated with cisplatin based chemotherapy (BEP or EP).

Secondary Objective(s):

-To explore the short- and long-term consequences of taste and smell changes in relation to food preference, dietary intake, and quality of life in patients with disseminated testicular cancer treated with cisplatin based chemotherapy. -To investigate the appreciation of (medical) food products in patients with disseminated testicular cancer treated with cisplatin based chemotherapy.

Study design

The present study will have a longitudinal (with measurements before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and a cross-sectional (with measurements 1, 3, 5 and 7 years after chemotherapy) design. Patients can start participation in this study before the start of their chemotherapy, which will result in longitudinal data of these patients or they can start participation years after treatment, resulting in cross-sectional data.

Study burden and risks

Performing the measurements, and filling out the questionnaires is considered as a minimal burden for the testicular cancer patients. With this study we hope to get insight into the nature, prevalence, and duration of taste and smell changes and their significance for food preference, dietary intake and quality of life. With knowledge regarding taste and smell changes, a better prediction on food acceptance can be given at the start, during, and after chemotherapy to maintain a healthy eating pattern or, if necessary, improve the diet. Besides, this research will yield valuable information for industry with regard to further research and development in (medical) food products.

Contacts

Public Universitair Medisch Centrum Groningen

Hanzeplein 1 Groningen 9700 RB NL **Scientific** Universitair Medisch Centrum Groningen

Hanzeplein 1 Groningen 9700 RB NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Cancer patients:

- Testicular cancer patients treated with cisplatin based chemotherapy
- Age range 18-50
- Ability to comprehend Dutch (both reading and writing)
- Signed informed consent; Healthy controls:

4 - Taste and smell changes in testicular cancer patients treated with cisplatin bas ... 25-05-2025

- Healthy males
- Age 18-50 years
- Ability to comprehend Dutch (both reading and writing)
- Signed informed consent

Exclusion criteria

Cancer patients

- Mental disability
- -Smoking (cross-sectional part);Healthy controls:
- Mental disability
- Ever diagnosed with cancer
- History of taste and smell abnormalities
- Smoking (cross-sectional part)

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Other

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	10-07-2012
Enrollment:	140
Туре:	Actual

Ethics review

Approved WMO

5 - Taste and smell changes in testicular cancer patients treated with cisplatin bas ... 25-05-2025

Date:	12-04-2012
Application type:	First submission
Review commission:	METC Universitair Medisch Centrum Groningen (Groningen)
Approved WMO Date:	30-01-2013
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Groningen (Groningen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register CCMO

ID NL38757.042.11